Therefore, the analysis of phospho-PRAS40Thr246 expression levels could reflect PI3K pathway activation status and present a novel biomarker to identify HER2-amplified breast cancers that are unlikely to respond to trastuzumab-based therapy. This evidence concerns the gene PIK3CA and breast carcinoma.